Skip to content

Study · Randomized controlled trial · n = 24 · 2017

5 results

Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.

Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA, Driscoll DJ

American journal of medical genetics. Part A30 Mar 2017Cited by 94 (Europe PMC)

PMID28371242 (opens in a new tab)PMCIDPMC5828021 (opens in a new tab)DOI10.1002/ajmg.a.38160 (opens in a new tab)PepBankPUB-28371242
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, improvement in all scale factors from Day 3 to Day 6 favored intranasal oxytocin over placebo, without significance for any single factor.

    In plain wordsIn children with Prader-Willi syndrome, behavior scale scores improved more with oxytocin than with placebo, but no single score differed significantly.

    Peptide
    Oxytocin
    Outcome
    IncreaseQuestionnaire scale factor improvement, Day 3 to Day 6
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 5 daysAs given in this study (human).

    Source sentences

    Summary
    All scales factor improvement from Day 3 to Day 6 favored oxytocin over placebo.
    1 context sentence
    Summary · context
    We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, no single factor showed a statistically significant difference between oxytocin and placebo at Day 6.

    In plain wordsIn children with Prader-Willi syndrome, no single behavior score differed significantly between oxytocin and placebo at Day 6.

    Peptide
    Oxytocin
    Outcome
    No significant changeSingle factor difference at Day 6
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 5 daysAs given in this study (human).

    Source sentences

    Summary
    No single factor showed a statistically significant difference (P < 0.05) between groups at Day 6.
    1 context sentence
    Summary · context
    We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, the effect of intranasal oxytocin appeared to be diminished at Day 14.

    In plain wordsIn children with Prader-Willi syndrome, the effect of oxytocin appeared to fade by Day 14.

    Peptide
    Oxytocin
    Outcome
    DecreaseDrug effect at Day 14
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 5 daysAs given in this study (human).

    Source sentences

    Summary
    The drug effect appeared to be diminished at Day 14.
    1 context sentence
    Summary · context
    We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source.
  4. 04HumanRandomized controlled trialSafety outcome

    In children with Prader-Willi syndrome, safety laboratory parameters and 60 min post-dose vital signs did not differ between oxytocin and placebo.

    In plain wordsIn children with Prader-Willi syndrome, safety blood tests and vital signs did not differ between oxytocin and placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSafety laboratory parameters and vital signs
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 5 daysAs given in this study (human).

    Source sentences

    Summary
    There was no evidence of a difference between oxytocin and placebo in safety lab parameters, 60 min post dose vital signs, weight, or diet parameters.
    1 context sentence
    Summary · context
    We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome, body weight and diet parameters did not differ between oxytocin and placebo.

    In plain wordsIn children with Prader-Willi syndrome, weight and diet did not differ between oxytocin and placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeWeight and diet parameters
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 5 daysAs given in this study (human).

    Source sentences

    Summary
    weight, or diet parameters.
    1 context sentence
    Summary · context
    We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.